Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested in clinical trials,1 demonstrating efficacy as a single agent in patients with relapsed/refractory multi- ple myeloma (RRMM). Daratumumab exerts direct antitumor and indirect immunomodulatory effects by targeting CD38, a cell surface receptor highly expressed on neoplastic plasma cells.
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study / Attardi, Enrico; Pilerci, Sofia; Attucci, Irene; Buzzichelli, Alessandra; Messeri, Maria; Staderini, Michela; Vannucchi, Alessandro M; Antonioli, Elisabetta. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - ELETTRONICO. - 21:(2021), pp. e850-e852. [10.1016/j.clml.2021.06.018]
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study
Attardi, Enrico;Pilerci, Sofia;Attucci, Irene;Buzzichelli, Alessandra;Messeri, Maria;Staderini, Michela;Vannucchi, Alessandro M;Antonioli, Elisabetta
2021
Abstract
Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested in clinical trials,1 demonstrating efficacy as a single agent in patients with relapsed/refractory multi- ple myeloma (RRMM). Daratumumab exerts direct antitumor and indirect immunomodulatory effects by targeting CD38, a cell surface receptor highly expressed on neoplastic plasma cells.
| File | Dimensione | Formato | |
|---|---|---|---|
|
S2152265021002470.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
132.03 kB
Formato
Adobe PDF
|
132.03 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
